IL6 and ovarian carcinoma: The findings suggest that while IL6 inhibition alone may have limited standalone clinical efficacy, combining it with other therapeutic agents, particularly chemotherapies or pathway inhibitors, holds significant promise for improving outcomes in ovarian cancer patient.